Fundraising Foxときわバイオ株式会社
2 known investors
Find your way into ときわバイオ株式会社
Sign up to see every warm intro you have to ときわバイオ株式会社
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ときわバイオ株式会社 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Tokiwa Bio develops the Stealth-type RNA vector (SRV™), a non-integrating gene delivery vector that can introduce multiple or large genes into cells at high efficiency for gene therapy. The company also applies SRV™ to cell reprogramming for regenerative medicine and to biopharmaceutical manufacturing.
Investors · 2
Frequently asked questions
- What does ときわバイオ株式会社 do?
- Tokiwa Bio develops the Stealth-type RNA vector (SRV™), a non-integrating gene delivery vector that can introduce multiple or large genes into cells at high efficiency for gene therapy. The company also applies SRV™ to cell reprogramming for regenerative medicine and to biopharmaceutical manufacturing.
- Who are ときわバイオ株式会社's investors?
- ときわバイオ株式会社's investors include Kyoto University Innovation Capital, TOHOKU University Venture Partners.